临床试验药物安全性

关键字：类型：

下载页码(大于0,小于852)：

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

临床试验药物安全性 1506条(本栏目收费,不能显示细节,电话13136136841)

Cumulative toxicity basis of exclusion,94,96 94 96

Cyclophosphamide,329,602 329 602

Cyclosporin A,699,700 699 700

Cysteamine bitartrate,27 27

for nephropathic cystinosis,79 79

Cystic fibrosis,777 777

Conductance Regulator(CFTR),777 777

component,576,577 576 577

modulation of immune system,586 586

Cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4),603,605 603 605

Czito schema,46 46

Dasafinib for chronic myeloid leukemia,165,166 165 166

Committee (DSMC),500,501,561,562,720,727 500 501 561 562 720 727

Data manager,functions,530,532 530 532

Data Monitoring Committee (DMC),23,500,501,561,562,720 23 500 501 561 562 720

Dear Healthcare Professional letters,485,549,553 485 549 553

Decision aid informed consent,683,686 683 686

Decision tree Baselga schema,47 47

Katsumata schema,48,50 48 50

run-in period,76,77 76 77

Decision-making process on adverse events that appear irrelevant to the study drug,541,542 541 542

dimethyl fumarate for multiple sclerosis,541 541

everolimus for preventing rejection of kidney transplants,542 542

overview,695,696 695 696

AUC (area under the curve),23 23

Authority of FDA inspectors,720,721 720 721

maintenance therapy in,328,330 328 330

5-Aza-deoxycytidine myelodysplastic syndrome management,353 353

Azathioprine,329 329

Azithromycin,144,195 144 195

最新招商产品更多>>

浙ICP备16010490号-2 增值电信业务经营许可证：浙B2-20220931　互联网药品信息服务资格证书编号：(浙)-经营性2023-0215　

浙公网安备:330683240604819103159
　医药代理商群１：

医药代理商群２：

医药代理商群３：